Silence Therapeutics (SLN) Common Equity (2018 - 2026)

Silence Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $49.4 million for Q1 2026.

• In Q1 2026, Common Equity fell 56.18% year-over-year to $49.4 million; the TTM figure through Mar 2026 stood at $49.4 million (down 56.18% YoY), while the FY2025 annual figure was $62.3 million, down 53.51% from the prior year.
• Common Equity came in at $49.4 million for Q1 2026 at Silence Therapeutics, down from $62.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $156.8 million in Q1 2024 to a low of -$6.0 million in Q2 2022.
• A 5-year average of $64.7 million and a median of $49.4 million in 2026 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 118.04% in 2022 and soared 829.32% in 2024, its largest moves.
• Silence Therapeutics' Common Equity stood at $25.9 million in 2022, then declined by 18.26% to $21.2 million in 2023, then jumped by 533.33% to $134.0 million in 2024, then slumped by 53.51% to $62.3 million in 2025, then dropped by 20.71% to $49.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $49.4 million, $62.3 million, and $74.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison